Squamous cell carcinoma of the buccal mucosa: an aggressive cancer requiring multimodality treatment

BACKGROUND: In our clinical practice, we have observed a high incidence of locoregional failure in squamous cell carcinoma (SCC) of the buccal mucosa. We analyze our treatment results of this cancer and compare these results with those in the literature. We intend to define the pattern and incidence of failure of buccal cancer and provide information for the design of a better multimodality treatment. METHODS: During the period from 1983 through 2003, 121 previously untreated patients with M0 stage SCC of the buccal mucosa were treated with a curative intent at our hospital. Twenty-seven patients received surgery alone, 36 had radiotherapy alone, and 58 underwent surgery plus postoperative radiotherapy. RESULTS: The 5-year locoregional control, overall survival, and cause-specific survival rates for all patients were 36.3%, 34.3%, and 36.9%, respectively. The locoregional recurrence rate was 57% for all patients, with 80% occurring in the primary site alone. Patients with T1-2N0 disease who received surgery alone still had a high local recurrence incidence of 41%. For patients with locally advanced disease, surgery plus postoperative radiotherapy achieved better overall survival and locoregional control rates than surgery alone or radiotherapy alone. T classification was the only prognostic factor affecting locoregional control and survival in the surgery alone group, whereas N classification and skin invasion predicted a poorer survival for the surgery plus postoperative radiotherapy group. CONCLUSIONS: SCC of the buccal mucosa is an aggressive cancer with a high locoregional failure rate even in patients with T1-2N0 disease. Possible reasons include inadequate treatment and an intrinsically aggressive nature. Postoperative radiotherapy has resulted in a better locoregional control rate for patients with T3-4 or N+ disease and should also be considered for patients with T1-2N0 disease for whom adjuvant therapy after radical surgery currently is not recommended by most guidelines.     

Carcinoma of the tongue: the Montreal General Hospital experience from 1979 to 1984

In a retrospective study of 54 patients with primary carcinoma of the tongue seen at the Montreal General Hospital from 1979 to 1984, the overall 2-year survival for those with stage I disease was 92%. Surgery alone was the initial treatment in 84% of these patients. Disease recurred in 36%. In stage II patients, 8 of 12 had surgery followed by radiotherapy; 37% had recurrent disease. Surgery alone was used in 4 of 12 and with recurrence in 3. Overall survival in stage II was 83% at 2 years. In cases of localized disease, the survival rate for surgery alone was not significantly different from that after surgery plus radiotherapy. Combined surgery plus radiotherapy might offer better regional control in stage II disease. Of 18 stage III patients, 7 were treated by surgery followed by radiotherapy; 3 died and 4 are disease free. All had commando procedures. Radiotherapy alone was used in seven and six of them had recurrences. Overall, the 2-year survival for stage III was 61%. Control of regional disease was achieved in 57% of those who had surgery plus radiotherapy as opposed to 39% overall. Stage IV patients had a 2-year survival of 10%. Nine of the 11 received chemotherapy followed by radiotherapy. This combination did not improve survival and most of these patients died within 1 year.     

Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group

BACKGROUND: We analyzed the records of patients with malignant salivary gland tumors, as diagnosed in centers of the Dutch Head and Neck Oncology Cooperative Group, in search of independent prognostic factors for locoregional control, distant metastases, and overall survival. METHODS: In 565 patients, we analyzed general results and looked for the potential prognostic variables of age, sex, delay, clinical and pathologic T and N stage, site (332 parotid, 76 submandibular, 129 oral cavity, 28 pharynx/larynx), pain, facial weakness, clinical and pathologic skin involvement, histologic type (WHO 1972 classification), treatment, resection margins, spill, perineural and vascular invasion, number of neck nodes, and extranodal disease. The median follow-up period was 74 months; it was 99 months for patients who were alive on the last follow-up. RESULTS: The rates of local control, regional control, distant metastasis-free and overall survival after 10 years were, respectively, 78%, 87%, 67%, and 50%. In multivariable analysis, local control was predicted by clinical T-stage, bone invasion, site, resection margin, and treatment. Regional control depended on N stage, facial nerve paralysis, and treatment. The relative risk with surgery alone, compared to surgery plus postoperative radiotherapy, was 9.7 for local recurrence and 2.3 for regional recurrence. Distant metastases were independently correlated with T and N stage, sex, perineural invasion, histologic type, and clinical skin involvement. Overall survival depended on age, sex, T and pN stage, site, skin and bone invasion. CONCLUSIONS: Several prognostic factors for locoregional control, distant metastases, and overall survival were found. Postoperative radiotherapy was found to improve locoregional control.     

Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group.

The Edinburgh Lung Cancer Group prospectively registered 651 new patients presenting with lung cancer during 1981; only 47 survived five years (7%). The survival rate was highest in patients selected for surgery (35/116, 30%) and in this group was related to cell type, stage of disease, and possibly to Karnofsky performance score (not statistically significant). By comparison with non-surgical patients these 116 patients undergoing surgery were highly selected in terms of age, favourable histological type, stage of disease, and performance score. Forty-two of the 535 non-surgical patients were given radical radiotherapy alone and seven (17%) survived five years. The remaining 493 received palliative radiotherapy, chemotherapy (alone or combined with radiotherapy), or symptomatic treatment alone; only five (1%) survived five years. Median survival was related to cell type (adenocarcinoma 2.6 months, squamous cell carcinoma 6.2 months), stage (stage I 8.5 months, stage III 4 months), and Karnofsky performance index (greater than or equal to 90 9.3 months, less than or equal to 50 1.2 months). Age and sex had no independent prognostic value in any group. Performance score was highly correlated with stage (and age) and in this study represented the "best prognostic factor" in clinical practice.     

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

OBJECTIVE: The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme. MATERIAL AND METHODS: A total of 1218 patients were randomized on a 1:1 basis to either bicalutamide 150 mg/day (n=607) or placebo (n=611) following standard care; 81.4% were followed conservatively (watchful waiting). The primary endpoints were objective progression-free survival (PFS) and overall survival (OS). RESULTS: In patients with localized disease there was no significant difference in PFS [hazard ratio (HR) 0.85; 95% CI 0.69-1.06; p=0.15] and a trend towards decreased OS with bicalutamide plus standard care compared with standard care alone (HR 1.23; 95% CI 0.96-1.58; p=0.11). In patients with locally advanced disease, bicalutamide significantly improved PFS, reducing the risk of progression by 53% compared with standard care alone (HR 0.47; 95% CI 0.37-0.59; p<0.001). The median time to progression was 8.8 years for bicalutamide plus standard care and 7.1 years for standard care alone. There was a significant improvement in OS with bicalutamide plus standard care, with a reduction in the risk of death of 35% versus standard care alone (HR 0.65; 95% CI 0.50-0.85; p=0.001). CONCLUSION: This analysis of the SPCG-6 study showed that bicalutamide plus standard care offers significant PFS and OS benefits for patients with locally advanced disease, but not for those with localized disease.     

Control of regional metastasis after induction chemotherapy and radiotherapy for nasopharyngeal carcinoma

BACKGROUND: To study the impact of adding induction chemotherapy to radiotherapy on the long-term control of regional metastasis and survival in patients with nasopharyngeal carcinoma (NPC). METHODS: Between February 1988 and August 1993, 240 NPC patients with Ho's T3 stage, N2-3 stage, or nodal size >/=3 cm were recruited onto two randomized trials comparing induction chemotherapy followed by radiotherapy (CT + RT) and radiotherapy alone (RT) using a similar treatment protocol. Of these, 210 patients (105 in each treatment arm) had cervical nodal metastasis and were included in the analysis. Patients in the CT + RT arm received two to three cycles of cisplatin, 60 mg/m(2) day 1, + epirubicin, 110 mg/m(2) day 1, followed by radiotherapy. Radiotherapy technique and dose were similar in both arms. The median follow-up time was 71 months (range, 5-152 months). RESULTS: The overall response rate of nodal disease to chemotherapy was 86%, and the complete response (CR) rate was 44%. At the end of radiotherapy, 92% of patients in the CT + RT arm and 86% in the RT arm achieved CR in the neck (p =.12). The 5-year nodal relapse-free survival rates in the CT + RT and RT arm were 83% and 75%, respectively (p =.13). Most neck failures (81%) occurred during the first 36 months of follow-up. Radical neck dissection successfully salvaged 41% of neck failures in the CT + RT arm and 46% in the RT arm. The 5-year distant metastases-free survival rates were 70% in the CT + RT arm and 68% in the RT arm (p =.56), and the corresponding 5-year disease-specific survival rates were 66% and 68%, respectively (p =.55). In subgroup analysis, no significant differences in regional control and survival could be found in patients with Ho's N2-3 stage, AJCC N2-3 stage, or nodal size >6 cm. CONCLUSIONS: Induction chemotherapy does not seem to improve the regional control and survival in NPC patients with regional metastasis compared with radiotherapy alone and is not recommended as a routine treatment outside the context of a clinical trial.     

Primary gastric lymphoma

This is a population-based review of 153 cases of primary gastric lymphoma. Sixty-seven (43 per cent) were histologically reviewed using the Kiel classification. There were no significant differences between reviewed and unreviewed cases. Ninety-seven per cent of all cases were of the non-Hodgkin's type. The annual incidence was constant at 1.2 per cent of gastric malignancies. The mean age was 60 years and the male to female ratio 1:8. Presenting symptoms were similar to those of gastric cancer. Twenty-one per cent had a palpable mass but one-third of these were amenable to a potentially curative resection. Some 66 per cent were resectable and 58 per cent had a macroscopic clearance of tumour. TNM stage and absolute tumour size were significant prognostic factors (P less than 0.005 and P less than 0.05 respectively) but the Kiel classification was not. The overall 5 year survival was 24 per cent. Apart from 10 patients whose only anti-tumour treatment was radiotherapy (5 year survival 36.9 per cent) no patient who did not have curative surgery survived 5 years. The 5 year survival for curative resection was 34 per cent and for curative resection plus radiotherapy was 43.5 per cent (45 and 73.4 per cent for the node negative cases respectively). A laparotomy is essential; 'curative' surgery possibly with adjuvant radiotherapy offers the best hope for cure.     

直肠癌术后局部复发综合治疗的疗效分析

目的：分析直肠癌根治术后局部复发的类型、综合治疗的疗效及预后。方法：对直肠癌术后局部复发、以往未接受过放疗的66例病人进行疗效分析。原手术方式为经腹直肠切除术45例(Dixon术40例，Parks术5例)，腹会阴直肠切除术21例。经腹直肠切除术后复发以吻合口为主(37／45，82．2％)，腹会阴直肠切除术后复发则以盆腔或会阴为主(19／21，90．5％)。复发后盆腔放疗中位剂量为40(20—64）Gy，临床症状缓解中位剂量26(10～52)Gy。其中26例在放疗过程中或之后接受过中位7个(2～12)疗程以5-FU为主的化疗。有22例放疗后获补救手术机会。结果：全组中位生存期24个月。Kaplan-Merier法计算生存率，放疗后1、3年总生存率分别为72．2％、17．9％。单因素分析并Log rank检验生存率差异，显示生存率与原发病变的期别、术后复发时间、复发部位及是否加用化疗无关，而仅与是否再次行补救手术有关。放疗后加用补救手术者3年生存期明显较长，为36．0％比8．8％(P=0．016)。结论：直肠癌根治术后局部复发者，放疗具有良好的姑息减症的作用；对部分经腹直肠切除术后的复发病例，放射治疗加补救手术能明显延长生存期。     

脾脏原发性恶性淋巴瘤29例临床分析

目的 分析原发性脾脏恶性淋巴瘤的临床特征.方法 回顾性分析2000年11月至2008年8月收治的29例脾脏原发性恶性淋巴瘤患者的临床资料. 结果29例患者中,非霍奇金淋巴瘤27例,霍奇金淋巴瘤2例.根据Ahmann脾淋巴瘤临床分期,Ⅰ期6例,Ⅱ期4例,Ⅲ期19例.26例患者进行了脾脏切除术,2例因病变侵犯胰尾而行脾脏切除+胰体尾切除术,1例因侵犯胃行脾脏切除+部分胃切除术.术后19例患者接受了辅助性化学治疗,5例使用利妥昔单抗(美罗华).1例患者接受了区域淋巴结放射治疗.中位随访时间24个月(2～93个月),脾脏原发性恶性淋巴瘤1、3和5年的总生存率分别为:96%、83%和73%,1、3和5年的无瘤生存率分别为96%、51%和51%.结论 脾脏原发性恶性淋巴瘤是最常见的原发性脾脏恶性肿瘤,手术切除脾脏及其周围受累器官是重要的治疗方法,手术后应当辅以化疗、放疗、生物治疗等措施.     

Limitations of radiotherapy in the definitive treatment of squamous carcinoma of the tonsillar fossa.

Between 1970 and 1990, 104 patients with squamous cell carcinoma (SCC) of the tonsil were treated. The median age was 58 years and 80% of patients were males. Distribution among clinical stages was: stage I, 19 patients; stage II, 12 patients; stage III, 23 patients; and stage IV, 48 patients. More than 70% of patients had initial radiotherapy as definitive treatment irrespective of stage, reflecting the treatment philosophy over much of this period. The overall survival rate was 26% at 5 years, with survival being significantly affected by T stage, clinical stage and age. Clinical node status did not significantly affect survival rates. Good local control of T1N0 cancers was achieved with radiotherapy alone, but patients with more advanced cancers did poorly. We have now moved away from a non-selective policy and use initial surgery combined with postoperative radiotherapy in most patients, reserving radiotherapy alone for mainly early tonsil cancers.     

Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients

OBJECTIVES: To evaluate the clinical presentation and treatment end results of primary adenocarcinoma of the urinary bladder, and to determine the significant independent prognostic factors that determine this outcome. PATIENTS AND METHODS: Of 3659 patients who underwent cystectomy, 192 had adenocarcinoma of the urinary bladder, with a relative frequency of 5.2%. Most of these patients (68.2%) presented in late stages (P3 + P4). The incidence of pelvic lymph nodes involvement was 25.5%. Mucinous adenocarcinoma was reported in 28 patients (14.6%), papillary in 20 (10.4%), signet ring in 14 (7.3%), while not otherwise specified was reported in 130 (67.7%) in the cystectomy specimens. RESULTS: Mucinous and signet-ring histologic subtypes showed increased frequency of high stages and high grades, and more nodal involvement than the papillary and not otherwise specified. All patients were treated with radical cystectomy and pelvic lymphadenectomy with (69 patients) or without (123) postoperative radiotherapy. The 5-year disease-free survival rate was 46 +/- 4% for all patients with adenocarcinoma. Postoperative radiotherapy improved the disease-free survival significantly. The 5-year disease-free survival rate for the postoperative radiotherapy group was 61 +/- 6% compared to 37 +/- 5% for the cystectomy alone group (P = 0.002). Local control rate was significantly improved from 53 +/- 7% for cystectomy alone to 96 +/- 3% for postoperative radiotherapy patients (P = 0.00001). Distant metastases were the leading cause of death in the postoperative radiotherapy group. CONCLUSIONS: Within the limitations provided by retrospective studies, it could be concluded that postoperative radiotherapy improved the disease-free survival through its effect on local control. The disease-free survival independent prognostic variables were tumor stage, postoperative radiotherapy, nodal involvement, and adenocarcinoma subclassification. These factors, except the adeno-subclassification, were also found to determine the local control rate. On the other hand, the independent prognostic factors for distant metastasis were lymph nodal involvement, stage, and adeno-subclassification.     

High-grade carcinoma of the prostate: a comparison of current local therapies

Objectives. To determine the impact of either single or combined local therapeutic modalities for poorly differentiated (Gleason score 8 to 10) prostate cancer.Methods. Between 1987 and 1996, 156 patients were diagnosed with biopsy proven, poorly differentiated (Gleason score 8 to 10), clinically localized prostate cancer. Of these patients, 87 were treated with radical prostatectomy alone, 19 with radiotherapy, and 24 with both prostatectomy and postoperative radiotherapy.Results. The median follow-up time was 74.6 months. The 5-year biochemical progression-free survival (PFS) for patients with a Gleason score of 8 to 10 was 65%, 30%, and 20% for patients treated with surgery plus postoperative radiotherapy, radiotherapy alone, and surgery alone, respectively (P <0.0001 between postoperative radiotherapy and all other groups, P = 0.6131 between surgery and radiotherapy). The 5-year clinical PFS was 80%, 60%, and 35% for patients treated with surgery plus postoperative radiotherapy, radiotherapy alone, and surgery alone (P <0.0001 between postoperative radiotherapy and all others, P = 0.1975 between surgery and radiotherapy). The independent prognosticators for biochemical failure included serum prostate-specific antigen level greater than 20 ng/mL and seminal vesicle invasion; only seminal vesicle invasion was prognostic for clinical failure.Conclusions. Patients with high-grade prostate cancer (Gleason score 8 to 10) have uniformly poor, but apparently similar, biochemical and clinical PFS rates when treated by either prostatectomy or radiotherapy alone. The addition of postoperative radiotherapy in the treatment of these patients may be associated with improved biochemical and clinical PFS compared with either modality alone.     

胃粘膜相关淋巴组织淋巴瘤的外科治疗

目的 探讨胃粘膜相关淋巴组织淋巴瘤外科治疗经验。方法 回顾性复习1984－1996年手术治疗的69例胃粘膜相关淋巴组织淋巴瘤患者的临床资料。结果 69例中I期26例Ⅱ期21例、Ⅲ期13例、Ⅳ期9例,全组病例均经手术及理证实。病变完全切除者61例,部分切除者4例,未切除者4例。单纯手术切除者5例,手术加放疗25例,手术加化疗19例,手术加放疗、化疗20例。全组总的5年生存率71％（49／69）,10年生存率31．9％（22／69）。结论 临床分期及治疗方法是影响预后的主要因素,年龄与性别与预后无关。外科手术在胃粘膜相关淋巴组织淋巴瘤治疗中是重要治疗手段。     

Adjuvant radiotherapy influences the survival of patients with squamous carcinoma of the head and neck who have poor prognoses.

The treatment of carcinoma of the head and neck in recent years has improved significantly, chiefly thanks to progress in surgery and radiotherapy. Despite these advances, the survival statistics reported in the literature show no appreciable evidence of radical improvement. The aims of this study were to evaluate the impact on survival achieved with the combination of surgical and postoperative radiotherapy in patients with advanced head and neck carcinomas and to identify the prognostic value of several host- and tumor-related factors that can influence the results of combined treatment. We retrospectively reviewed the medical records of 394 patients with stage III and IV carcinoma of the head and neck, of whom 170 (43%) underwent surgery alone and 224 (57%) received combined surgery and postoperative radiotherapy. The 394 patients were stratified for a set of variables including the patient's condition, the characteristics of the tumor, and the modality of treatment. Univariate analysis revealed that coexistent medical diseases, the size and site of the primary lesion, the stage of the tumor, and certain pathologic features had a negative impact on survival. Multivariate analysis showed that the removal of lymph nodes and postoperative radiotherapy can have a positive influence and can improve the prognosis. We compared the survival rates of the patients treated with surgery alone with those of the patients who underwent combined treatment, and we observed that the two survival curves were comparable, even if there was a bias because the combined treatment group consisted of patients with negative prognostic factors. The meaning of these results, compared with data from the literature, has been discussed.     

Ewing's sarcoma of the femur: Prognosis in 69 patients treated by the CESS group

We reviewed the treatment outcome of 69 patients with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.     

睾丸原发非霍奇金淋巴瘤

目的 分析睾丸原发非霍奇金淋巴瘤的临床表现、病理特征和治疗情况. 方法 睾丸原发淋巴瘤患者12例.年龄36～78岁.平均62岁.首诊症状:单纯睾丸增大8例;睾丸增大伴阴囊胀痛3例,伴发热1例;阴囊下坠1例.单侧11例,双侧1例.病程15 d～6个月.12例超声检查均有睾丸实质性肿块.10例行CT检查发现腹膜后淋巴结肿大3例.Ann Arbor分期ⅠE 9例、ⅡE2例、ⅢE 1例.12例均行根治性睾丸切除术,10例术后接受CHOP方案(环磷酰胺,阿霉素,长春新碱,泼尼松)化疗4～8个疗程.5例在化疗后行放射治疗,放疗剂量25～50 Gy. 结果 12例术后病理报告均为非霍奇金淋巴瘤,高度恶性3例、中度恶性9例.免疫分型:B细胞型8例,T细胞型2例,分类不明确2例.随访1～9年,失访1例.术后2年非癌死亡1例.1、3、5年生存率分别为82%(9/11),40%(4/10),20%(2/10).肿瘤复发转移部位包括对侧睾丸3例,中枢神经系统3例,肝转移1例,腹膜后广泛转移1例. 结论 睾丸原发非霍奇金淋巴瘤生存率低,应采取综合治疗.Ⅰ E、ⅡE期患者应给予手术加放射治疗加化疗,对侧睾丸应预防性照射.ⅡE期以上患者术后应先行化疗,然后根据病情辅以放射治疗.     

Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer

HYPOTHESIS: Despite aggressive approaches, locoregional tumor control and survival rates for patients with cancer of the pancreatic head remain disappointing. In the present study, we address whether intraoperative and adjuvant radiotherapy may improve the prognosis for these patients. DESIGN: A retrospective study. SETTING: University hospital. PATIENTS: From February 1985 to December 1995, 46 patients with an adenocarcinoma of the pancreatic head underwent pancreatic resection. The last 26 patients also received intraoperative radiotherapy (except 5 patients) and adjuvant external beam radiation therapy. MAIN OUTCOME MEASURES: Demographic data, tumor characteristics, surgical procedures, 5-year survival, and local control of disease were analyzed retrospectively. RESULTS: The morbidity rate was not increased by adjuvant radiation therapy; it was 43% in patients treated with surgery alone and 57% in patients treated with surgery and radiotherapy (P =.1); operative mortality was 8% (n = 2) and 9% (n = 2), respectively (P =.8). Overall 5-year survival and local control were 13% and 48.6%, respectively. The mean +/- SD 5-year survival was 5.5% +/- 5.3% (median, 10.8 months) in the surgery-alone group and 15.7% +/- 8.6% (median, 14.3 months) in the surgery plus radiotherapy group (P =.06); local control at 5 years was 29.8% +/- 16.9% and 58.4% +/- 19.9%, respectively (P<.01). Median metastasis-free survival was 8 and 9 months, respectively (P =.52). Multivariate analysis showed that adjuvant radiotherapy was an independent prognostic factor for survival (P<.01) and local control of the disease (P =.03). CONCLUSION: The present study supports the role of radiotherapy combined with pancreatoduodenectomy for treatment of cancer of the pancreatic head because even if the improvement in overall survival is moderate, it is effective in improving the local control of the tumor.     

Treatment of thymomas. A report of 67 cases.

From 1979 to 1989, 126 patients were treated for thymic tumors. Of these, 67 (53%) had thymomas occurring in 27 men and 40 women; the mean age was 46 years: 24 patients had no symptoms and myasthenia gravis was present in 21 cases. A complete resection was performed in 45 patients, associated in 22 with postoperative adjuvant treatment (radiotherapy, 2; radio- and chemotherapy, 20). Two patients had a partial resection followed by radiotherapy and chemotherapy. Twenty patients had initially only a biopsy and were treated by irradiation in 3 cases, radio- plus chemotherapy in 16, radio- plus chemotherapy and subsequent resection in 1 case. The staging was carried out according to the GETT Classification (stage I A:26; I B:6; II:12; III A:1; III B:18; IVA:4). Thymomas were found to be of predominant epithelial type in 12 cases, predominantly lymphocytic type in 9, and mixed in 46. No recurrence occurred after complete resection. The overall 10-year survival was 71.1%. A good correlation was found according to staging: 96% in stage I; 80% in stage II; 35% in stage III. Presence of myasthenia gravis did not affect the results. The best prognostic factor remains complete resection with postoperative radiotherapy to prevent recurrences. The role of adjuvant chemotherapy needs further evaluation.     

原发性输尿管癌影响预后因素分析

目的　探讨原发性输尿管癌影响预后因素及术后发生膀胱癌的危险因素。　方法　16 0例输尿管癌中男 93例 ,女 6 7例 ,平均年龄 6 3.7岁。左侧 81例 ,右侧 79例 ;上段 30例 ,中段 2 1例 ,下段 96例 ,单侧多发 13例。病理分期Ta9例 ,T15 8例 ,T2 4 6例 ,T3 4 1例 ,T46例 ;分级G14例 ,G2 119例 ,G3 37例。 16 0例均行手术治疗 ,其中肾、输尿管全长加膀胱袖状切除 12 4例 (77.5 % )。总结临床病理学资料 ,对随访结果进行统计学分析。　结果　患者 5年生存率 5 3.0 % ,其中Ta、T1、T2 患者 5年生存率 (83.3%、71.9%、5 9.1% )与T3 和T45年生存率 (37.5 %、16 .7% )比较差异有统计学意义 (P <0 .0 0 0 1) ;G1、G2 患者的 5年生存率 (10 0 .0 %、6 3.5 % )与G3 (19.0 % )比较差异有统计学意义 (P =0 .0 0 1)。肿瘤分期分级是影响预后的因素。 16 0例输尿管癌术后发生膀胱癌者 38例 (2 3.8% )。多因素分析结果显示 ,伴有同发膀胱癌和下段输尿管癌是术后发生膀胱癌的危险因素 (P =0 .0 0 1,P =0 .0 0 5 )。　结论　原发性输尿管癌分期分级是影响预后因素 ;伴有同发膀胱癌和下段输尿管癌是术后发生膀胱癌的危险因素。     

The effect of primary tumor volumes in advanced T-staged nasopharyngeal tumors

BACKGROUND: Tumor volume is an important prognostic factor in patients with malignancy treated with primary radiotherapy. It is necessary to have a clear understanding of the nasopharyngeal primary tumor volume and the treatment outcome, especially in the advanced T-staged tumors. METHODS: From 1994-1996, 76 newly diagnosed patients with advanced T-staged nasopharyngeal carcinomas who were treated with high-dose radiotherapy with or without chemotherapy were included in this study. CT-derived primary tumor volume was obtained after the summation of area technique. RESULTS: The median primary tumor volume was 29.6 mL in T3 disease and 54.1 mL in T4 disease, with a range of 8.0-131.8 in T3 disease, and 6.7-223.1 ml in T4 disease. Large primary tumor volume was associated with a significantly poor disease-specific survival (p <.0001), whereas the T stage carried no prognostic significance (p =.43). CONCLUSIONS: In advanced T-staged (T3 and T4) nasopharyngeal tumors, a substantial variation of primary tumor volume was present within the same T stage, and primary tumor volume represented a more important prognostic factor for treatment outcome. Volumetric measurements of primary tumors in advanced nasopharyngeal tumors would refine the TNM staging system. Patients with large primary tumor volume should be treated more aggressively.